Aridis Pharmaceuticals Inc. (ARDS)

Overview

Aridis Pharmaceuticals, Inc. is a distinguished late-stage biopharmaceutical company primarily engaged in discovering and developing advanced targeted immunotherapies. These therapies are predominantly leveraged fully human monoclonal antibodies (mAb) to efficaciously treat life-threatening infections. Established in 2003 and with its headquarters located in Los Gatos, California, Aridis Pharmaceuticals is at the forefront of immunotherapy, focusing on addressing critical needs in the treatment of severe infections. Through its dedicated research and innovative approach, the company endeavors to bring transformative treatments to patients suffering from infectious diseases, highlighting its vital role in the biopharmaceutical industry.

Products and Services

• AR-301

  AR-301 stands out as Aridis Pharmaceuticals’ leading product candidate, representing a fully human monoclonal antibody of the immunoglobulin 1 (IgG1) class. This antibody has successfully completed Phase III pivotal trials, targeting lung infections caused by S. aureus alphatoxin. Further, AR-301 is in development as an adjunctive therapy alongside standard of care (SOC) antibiotics, intended for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), showcasing its potential in combating critical respiratory infections.

• AR-320

  AR-320 is another fully human IgG1 monoclonal antibody under development, aimed at targeting infections caused by both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus. This product underscores Aridis Pharmaceuticals' commitment to addressing antibiotic resistance, a growing global health concern.

• AR 501

  AR 501 introduces an innovative therapeutic approach as an inhaled gallium citrate formulation. Currently in Phase 1/2a clinical trials, AR 501 is being investigated for the treatment of chronic lung infections associated with cystic fibrosis, illustrating the company's dedication to providing novel treatments for complex pulmonary diseases.

• AR-101

  AR-101, a human IgM monoclonal antibody, is actively undergoing Phase II clinical trials. Its target is the Pseudomonas aeruginosa liposaccharides serotype O11, positioning AR-101 as a critical component of Aridis Pharmaceuticals’ portfolio aimed at addressing severe bacterial infections.

• Preclinical Programs

  Aridis Pharmaceuticals also boasts several promising preclinical programs, including AR-401 for the treatment of infections caused by Acinetobacter baumannii, AR-201 targeting respiratory syncytial virus, and AR-701, a cocktail of two human immunoglobulin 1. These programs exemplify the company's innovative approach and continuous effort to expand its product pipeline to meet the urgent needs of patients suffering from a broad range of infectious diseases.